Typhoid fever in travelers: Who should be targeted for prevention?

Clinical Infectious Diseases

Volumn 39, Issue 2, 2004, Pages 186-191

  Steinberg, E B ^a,c,g   Bishop, R ^b   Haber, P ^d   Dempsey, A F ^f   Hoekstra, R M ^b   Nelson, J M ^a   Ackers, M ^e   Calugar, A ^d   Mintz, E D ^a  

^a Foodborne and Diarrheal Dis Branch   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c Epidemiology and Analysis Program Office   (United States)

^d CENTERS FOR DIS CONTR AND PREV   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TYPHOID VACCINE;

ADOLESCENT; ADULT; BANGLADESH; CHILD; CHILL; DEATH; DISABILITY; FEMALE; FEVER; HAITI; HEADACHE; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; INDIA; INFANT; MALE; MEXICO; NAUSEA; PAKISTAN; PHILIPPINES; PRIORITY JOURNAL; REVIEW; RISK; SALMONELLA ENTERICA; SEROTYPE; SIDE EFFECT; TRAVEL; TYPHOID FEVER; UNITED STATES; VACCINATION;

EID: 3242760477     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421945     Document Type: Review

References (15)

1. Edelman R, Levine NM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8:329-349.
2. Ryan CA, Hargrett-Bean NT, Blake PA. Salmonella typhi infections in the United States, 1975-1984: increasing role of foreign travel. Rev Infect Dis 1989; 11:1-8.
3. Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe RV. Typhoid fever in the United States, 1985-1994: changing risks of in ternational travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158:633-8.
4. Ackers ML, Puhr N, Tauxe R, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimi crobial resistance on the rise. JAMA 2000; 283:2668-73.
5. US Department of Health and Human Services (USDHHS). Healthy people 2010: understanding and improving health. Washington, DC: USDHHS, 2000.
6. Centers for Disease Control and Prevention. Typhoid immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994; 43(RR-14):1-7. Available at: http://www.cdc.gov/ mmwr/pdf/rr/rr4314.pdf. Accessed 1 July 2004.
7. Centers for Disease Control and Prevention (CDC). Health information for international travel, 2001-2002. Atlanta: CDC, 2001.
8. Singleton J. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 1999; 17:2908-17.
9. Olsen SJ, Bleasdale SC, Magnazo R, et al. Outbreaks of typhoid fever in the United States, 1960-1999. Epidemiol Infect 2003; 130:13-21.
10. Parry C, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002; 347:1770-82.
11. Lin F, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9.
12. Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003; 349:1390-1.
13. Begier EM, Burwen DR, Haber P, Ball R. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Report System, July 1990 through June 2002. Vaccine Adverse Event Report System Working Group. Clin Infect Dis 2004; 38:771-9.
14. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Morb Mortal Wkly Rep 2003; 52(SS-1):1-24.
15. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995; 85:1706-9.